LINFOMAS Y TRASPLANTES
Hospital Clinic Barcelona
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Clinic Barcelona (109)
2024
-
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
Transplantation and Cellular Therapy, Vol. 30, Núm. 2, pp. 210.e1-210.e14
2023
-
Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy
Transplantation and Cellular Therapy, Vol. 29, Núm. 7, pp. 430-437
-
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
Haematologica, Vol. 108, Núm. 1, pp. 110-121
-
Correction: Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era (Bone Marrow Transplantation, (2023), 58, 6, (673-679), 10.1038/s41409-023-01949-x)
Bone Marrow Transplantation
-
Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome
British Journal of Haematology, Vol. 200, Núm. 3, pp. 306-314
-
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study
The Lancet Oncology, Vol. 24, Núm. 8, pp. 913-924
-
IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia
Blood Advances
-
Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study
Transplantation and Cellular Therapy, Vol. 29, Núm. 12, pp. 747.e1-747.e10
-
Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation
Haematologica
-
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO
British Journal of Haematology, Vol. 203, Núm. 2, pp. 202-211
-
One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients
Blood Cancer Journal, Vol. 13, Núm. 1
-
Quantifying the available capacity and resource needs for provision of CAR-T therapies in the National Health Service in Spain: a survey-based study
BMJ open, Vol. 13, Núm. 7, pp. e071371
-
Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients
Viruses, Vol. 15, Núm. 10
-
Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era
Bone Marrow Transplantation, Vol. 58, Núm. 6, pp. 673-679
-
Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Clinical Cancer Research, Vol. 29, Núm. 20, pp. 4057-4067
-
Unraveling the genetics of transformed splenic marginal zone lymphoma
Blood Advances, Vol. 7, Núm. 14, pp. 3695-3709
2022
-
Allogeneic Hematopoietic Stem Cell Transplantation in Transformed Follicular Lymphoma (tFL): Results of a Retrospective Multicenter Study from GELTAMO/GETH-TC Spanish Groups
Cancers, Vol. 14, Núm. 22
-
Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience
Cancers, Vol. 14, Núm. 11
-
Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study
Haematologica, Vol. 107, Núm. 11, pp. 2675-2684
-
Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups
Frontiers in Immunology, Vol. 13